Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study evaluates the ability of the immunosuppressive drugs dexamethasone, cyclosporine,
FK506
and rapamycin, alone and in combination to suppress interleukin-1 beta (IL-1 beta) secretion in vitro by THP-1 cells when stimulated by
lipopolysaccharide
. All four drugs, when added to cell culture medium at therapeutic concentrations, significantly decrease secretion of the monokine to well below control levels. However, only dexamethasone completely suppresses IL-1 beta secretion in a dose-dependent fashion. Cyclosporine,
FK506
and rapamycin only partially suppress secretion of IL-1 beta at concentrations within their therapeutic ranges and increasing concentrations of the drugs do not result in further suppression of secretion. Likewise, the combination of any two of these three drugs does not provide any additional suppressive effect. Dexamethasone, however, when added in increasing concentrations in combination with any of the other drugs, results in further suppression of IL-1 secretion in a dose-dependent fashion. These data suggest that cyclosporine,
FK506
and rapamycin all share a common effect on the production of IL-1 beta, different from that of dexamethasone.
...
PMID:Modulation of interleukin-1 secretion by immunosuppressive drugs, alone and in combination. 755 78
The immunosuppressive effects of cyclosporin A,
FK506
, and rapamycin were compared in mouse and rat systems of in vitro cellular stimulation. The inhibitory profile of rapamycin was distinctly different in the two species. In mouse systems, rapamycin caused a dose-dependent inhibition of both Ca(2+)-dependent (concanavalin A (Con A), phytohemagglutinin (PHA), and phorbol 12-myristate 13-acetate + ionomycin) and Ca(2+)-independent (
lipopolysaccharide
and PMA + interleukin-2) activation, whereas in the rat only Ca(2+)-independent responses were inhibited. Rapamycin's lack of activity in Ca(2+)-dependent responses in the rat does not appear to reside in a general insensitivity of this pathway to inhibition as cyclosporin A and
FK506
demonstrated potent inhibitory activity. Additionally, rapamycin was able to block the inhibitory effect of
FK506
on rat cells stimulated with the Ca(2+)-dependent stimulus, Con A. These results indicate a further dissociation in the biological activity of rapamycin compared to cyclosporin A and
FK506
and may point to intriguing species differences in the immunosuppressive effects of these compounds in vitro.
...
PMID:Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. 769 Mar 17
Recently, we have described that anti-IgM antibodies profoundly inhibited the growth of BKS-2, an immature B cell lymphoma. In this report, we demonstrated that ionomycin alone at very low concentrations (20 nM) inhibited the growth of BKS-2 cells completely. The levels of intracellular Ca2+ induced by the inhibitory concentrations of ionomycin were comparable to those in anti-IgM-treated cells. The growth inhibition caused by ionomycin was reversed by phorbol 12-myristate 13-acetate and
lipopolysaccharide
. In addition, the immunosuppressants, cyclosporin A and
FK506
conferred significant protection from the negative signal induced by ionomycin. However, either cyclosporin A,
FK506
or
lipopolysaccharide
was not found to have direct effect on ionomycin-induced Ca2+ mobilization in BKS-2 cells. Also, ionomycin augmented the anti-IgM-induced growth arrest in these cells. Furthermore, BKS-2 cells that were exposed to anti-IgM or ionomycin underwent apoptosis as characterized by DNA fragmentation. Thus, the characteristics of growth inhibition induced by ionomycin and anti-IgM appeared to be similar in that phorbol 12-myristate 13-acetate,
lipopolysaccharide
, cyclosporin A and
FK506
caused significant reversal from such negative signals and both ionomycin and anti-IgM induced apoptosis in these cells. Altogether, these results showed that the elevation of intracellular Ca2+ alone was sufficient to inhibit the growth of some B lymphoma cells.
...
PMID:Elevation of cytosolic calcium is sufficient to induce growth inhibition in a B cell lymphoma. 769 6
Experimental data show that relatively low concentrations of 15-deoxyspergualin (DSG) inhibit the induction of cytotoxic T lymphocytes (CTL) and the generation of antibody-producing cells. Considerably higher concentrations of DSG are required to inhibit proliferative responses. In this in vitro study, the effects of DSG on CTL induction, on proliferative responses induced by different stimuli, and on the production of interleukins IL-1, IL-2 and IL-6 and IFN-gamma (gamma-interferon) were assessed and compared with the effects of CsA (cyclosporine A) and/or
FK506
. We confirmed the suppressive action of DSG on the generation of CTL. Quite unexpectedly, however, we found that, although DSG did not affect the proliferative response to allogeneic lymphocytes or a superantigen, it did inhibit proliferation of peripheral blood leucocytes (PBL) stimulated with Staphyloccus aureus. DSG was active even when added on day 2 of in vitro culture, suggesting that DSG does not inhibit early events. The fraction of CD3+ lymphoblasts and the CD4/CD8 ratio was lower in cells stimulated by S. aureus in the presence of DSG, showing a selective effect on CD3+CD4+ responder T lymphocytes. The proportion of IL-2 receptor (CD25) positive cells was also reduced by DSG treatment. Moreover, we found that DSG inhibited the proliferation induced by PHA (phytohaemagglutinin) but not by Con A (concanavalin A). This effect of DSG was time-dependent, since PHA induced proliferation was not affected until day 4 after stimulation, and indicated that DSG may inhibit proliferation induced via a CD2- but not via a CD3-mediated pathway. DSG did not influence the production of IL-2 or IFN-gamma or the
lipopolysaccharide
induced production of IL-2 or IL-6. In contrast, the production of IL-6 was inhibited when cells were stimulated by allogeneic lymphocytes, S. aureus, PHA or Con A. This suggested to us that the DSG-suppressed IL-6 production could be the basis for the other observed effects. We tried to mimic the DSG effects with antibodies and indeed found that the IL-6 specific antibodies had similar effects. Furthermore, recombinant IL-6 completely overcame the suppressive effects of DSG on S. aureus and PHA induced proliferation, whereas addition of IL-6 to DSG treated PBL only partly restored the cytotoxic activity of lymphoblasts induced by allogeneic cells. Thus, the inhibitory effect of DSG on de novo synthesis of IL-6 could explain some of its immunosuppressive effects, but additional DSG-sensitive steps are obviously involved in CTL induction and differentiation.
...
PMID:15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes. 884 90
FK506
treatment markedly increased survival rates of [BALB/c-->C3H/He] bone marrow and spleen (BM/Spl) chimeras which had severe graft-versus-host disease (GVHD), marking 91% survival rates on day 60. In contrast, none of the vehicle-treated allogeneic BM/Spl chimeras survived more than 43 days after bone marrow transplantation (BMT). All the [BALB/c-->C3H/He] bone marrow (BM) chimeras survived more than 60 days after BMT, regardless of
FK506
treatment. Alloreactive mixed lymphocyte reactions (MLRs) against alloantigens in donor, host, and third party on week 8 were markedly inhibited in the spleen cells from all the chimeras including [C3H/He-->C3H/He] (syngeneic) BM chimeras. On week 12, alloreactive MLRs were still low in
FK506
-treated allogeneic BM/Spl and BM chimeras although those against third party alloantigen in the spleen cells from vehicle-treated allogeneic BM chimeras and syngeneic BM chimeras gradually recovered. Somewhat nonspecific cytotoxic activities against these alloantigens were sometimes observed, especially in week 8. Mitogen-induced responses confirmed that the immunosuppressive activity of
FK506
was directed to T cells, since concanavalin A (ConA)- and phytohemagglutinin (PHA)-induced responses were completely inhibited, but
lipopolysaccharide
(
LPS
)- and pokeweed mitogen (PWM)-induced responses were not. Reverse-transcription polymerase chain reaction (RT-PCR) method suggested that perforin and granzyme B gene expressions were basically unchanged or rather increased in the spleen cells from
FK506
-treated allogeneic BM/Spl and BM chimeras. These gene expressions suggested that
FK506
exerted its immunosuppressive effect in murine allogeneic bone marrow chimeras without mediating perforin and granzyme B.
...
PMID:FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B. 971 49
Activated hepatic macrophages can provoke massive liver necrosis following endotoxin stimulation through microcirculatory disturbances due to sinusoidal fibrin deposition in rats pretreated with heat-killed Propionibacterium acnes. In these rats,
FK506
(tachlorinus) administered 24 h before and at the time of endotoxin injection, significantly attenuated liver injury compared with the rats given no
FK506
. The effect of
FK506
on hepatic macrophage activation and its action sites were studied in Propionibacterium acnes-treated rats. When rats received Propionibacterium acnes intravenously, hepatic-mRNA expression of interferon-gamma-inducing factor and interleukin-2 and splenic-mRNA expression of interferon-gamma were significantly increased compared with normal rats. Hepatic-mRNA expression of CD14, a receptor for
lipopolysaccharide
and its binding protein complex, was also increased preceding the expressions of the three cytokines in the liver and spleen.
FK506
administration attenuated hepatic-mRNA expression of interleukin-2 and both superoxide anions as well as tumour necrosis factor-alpha production by hepatic macrophages, but did not change CD14-mRNA expression in Propionibacterium acnes-treated rats. It is suggested that a cytokine network through interferon-gamma-inducing factor, interferon-gamma and interleukin-2 may operate during activation of hepatic macrophages in rats treated with heat-killed Propionibacterium acnes, while CD14 expression on the cells may increase independently of this network.
FK506
seems to attenuate such activation by suppressing hepatic interleukin-2 expression, without affecting CD14 expression on the cells.
...
PMID:Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. 979 34
Exposure to sulfite, a well-known air pollutant, induces inflammatory reactions characterized by neutrophil infiltration into the airways. Using a simple and sensitive assay for sulfite concentration in biological fluids, we demonstrate herein that human neutrophils released significant amounts of sulfite (1.0 nmol/h/10(7) cells) in response to
lipopolysaccharide
(
LPS
), a major component of bacterial endotoxin. A large proportion of the sulfite release by neutrophils was dependent on inorganic sulfate contained in culture media, suggesting production via the sulfate reducing pathway in this response. We also show that glucocorticoids and
FK506
completely inhibit
LPS
-mediated sulfite release by neutrophils. Given the well-known antimicrobial activities of sulfite, our results suggest that sulfite acts as a neutrophil mediator of host defense. A putative role of sulfite as an endogenous biological mediator is further underscored by the observation that in vivo administration of
LPS
is associated with a marked increase in the serum concentration of sulfite in Wistar rats. Inhibition of sulfite release by immunosuppressive agents may contribute to increased susceptibility to bacterial infection commonly associated with the administration of these drugs.
...
PMID:Sulfite is released by human neutrophils in response to stimulation with lipopolysaccharide. 982 63
1. Activation of macrophages with
lipopolysaccharide
(
LPS
) and low doses of interferon-gamma (IFN-gamma) induced apoptotic death through a nitric oxide-dependent pathway. 2. Treatment of cells with the immunosuppressors cyclosporin A (CsA) or
FK506
inhibited the activation-dependent apoptosis. 3. These drugs decreased the up-regulation of p53 and Bax characteristic of activated macrophages. Moreover, incubation of activated macrophages with CsA and
FK506
contributed to maintain higher levels of Bcl-2 than in
LPS
/IFN-gamma treated cells. 4. The inhibition of apoptosis exerted by CsA and
FK506
in macrophages was also observed when cell death was induced by treatment with chemical nitric oxide donors. 5. Incubation of macrophages with
LPS
/IFN-gamma barely affected caspase-1 but promoted an important activation of caspase-3. Both CsA and
FK506
inhibited pathways leading to caspase-3 activation. Moreover, the cleavage of poly(ADP-ribose) polymerase, a well established caspase substrate, was reduced by these immunosuppressive drugs. 6. CsA and
FK506
reduced the release of cytochrome c to the cytosol and the activation of caspase-3 in cells treated with nitric oxide donors. 7. These results indicate that CsA and
FK506
protect macrophages from nitric oxide-dependent apoptosis and suggest a contribution of the macrophage to innate immunity under conditions of immunosuppression of the host.
...
PMID:Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. 1020 1
1 The effects of the immunosuppressant drugs cyclosporin A and tacrolimus (
FK506
) on nitric oxide synthesis were examined in a murine macrophage cell line (J774) and rat vascular smooth muscle cells (VSMC) in culture for 24 and 48 h, respectively. 2 Cyclosporin A (0.01-10 microM) inhibited by up to 90% accumulation of nitrite induced by
lipopolysaccharide
(
LPS
) in both cell lines, but
FK506
(0.01-10 microM) had a weaker effect on nitrite accumulation in these cells. Cyclosporin A and
FK506
(at 1 microM) also significantly inhibited nitrite production induced by recombinant murine interferon-gamma (rIFNgamma) and recombinant murine interleukin-1beta (rIL-1beta) in J774 and VSMC, respectively. 3 In J774 cells, cyclosporin A (but not
FK506
) at 1 microM was inhibitory when co-incubated with the inducing agents but not when the cells were treated with the immunosuppressant before or after the inducer. In VSMC, nitrite production was inhibited by co-incubation of cyclosporin A or
FK506
with the inducer, or when the immunosuppressants were pre-incubated with cells. In contrast, N-monomethyl L-arginine (NMMA) abolished nitrite production when incubated with either cell type during or after addition of inducing agent, but not if cells were preincubated with NMMA. 4 RNA extracted from treated J774 and VSMC was subjected to reverse transcription-polymerase chain reaction (RT-PCR). Cyclosporin A, but not
FK506
, suppressed expression of mRNA for NOS2 in a concentration-dependent manner when co-incubated with
LPS
. 5 The fact that the potency difference between cyclosporin A and
FK506
for NO suppression is the opposite to that for inhibition of interleukin-2 generation suggests that the immunosuppressants act in J774 macrophages and VSMC through intracellular mechanisms that differ from those elucidated in T-cells. Cyclosporin A suppresses NOS2 gene transcription, but
FK506
acts post-transcriptionally to suppress NO generation in VSMC. 6 Taken together the present data suggest that therapeutic concentrations of cyclosporin A, but not
FK506
, might well suppress NO production, but
FK506
would not have this effect. Suppression of NO might contribute to the side effects of hypertension and nephrotoxicity associated with long-term use of cyclosporin A to prevent transplant rejection.
...
PMID:Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. 1051 Apr 43
Extracts of the vine-like plant Tripterygium wilfordii (TW) have been widely used in China as an immunosuppressant and anti-inflammatory drug for the treatments of rheumatoid arthritis, lupus erythematosus and other inflammatory disorders. In this study the molecular mechanisms of action of three TW extracts (ethanol, aqueous, polysaccharide) on the expression of inflammatory cytokines and adhesion molecules were investigated by RT-PCR and immunofluorescence binding techniques. The
lipopolysaccharide
(
LPS
)-mediated stimulatory effects of tumor necrosis factor-alpha (TNF-alpha) cytokine production and cell adhesion molecule (CD11c, CD18, CD14, CD54) expression in human monocytic THP-1 cells were modulated by treatments of the TW extracts or tacrolimus (
FK506
). The TW polysaccharide moiety exhibited more profound immunosuppressive properties than the aqueous and ethanol extracts. Biochemical characterization of the polysaccharide moiety revealed a major molecular weight of 22 kDa (viz. PSP22). The PSP22 was found to be a potential immunosuppressant that manifests the necessary immunomodulating properties.
...
PMID:Suppression of cytokine production and cell adhesion molecule expression in human monocytic cell line THP-1 by Tripterygium wilfordii polysaccharide moiety. 1090 Dec 83
<< Previous
1
2
3
4
5
Next >>